Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May 4:3:103.
doi: 10.3389/fimmu.2012.00103. eCollection 2012.

Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities

Florencia Paula Madorsky-Rowdo  1 , María Laura Lacreu, José Mordoh
Affiliations

Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities

Florencia Paula Madorsky-Rowdo et al. Front Immunol. .

Abstract

To endow the immune system with the capacity to fight cancer has always attracted attention, although the clinical results obtained have been until recently disappointing. Cutaneous melanoma is a highly immunogenic tumor; therefore most of the attempts to produce cancer vaccines have been addressed to this disease. New advances in the comprehension of the mechanisms of antigen presentation by dendritic cells, in the immune responses triggered by adjuvants, as well as the understanding of the role of immunosuppressor molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), which led to the recent approval of the anti-CTLA-4 monoclonal antibody ipilimumab, have opened new hopes about the installment of immunotherapy as a new modality to treat cancer.

Keywords: CTLA-4; cancer vaccines; immunotherapy; melanoma.

PubMed Disclaimer

References

    1. Aris M., Zubieta M. R., Colombo M., Arriaga J. M., Bianchini M., Alperovich M., Bravo A. I., Barrio M. M., Mordoh J. (2012). MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. J. Invest. Dermatol. 132, 365–37410.1038/jid.2011.312 - DOI - PubMed
    1. Ascierto P. A., Marincola F. M., Ribas A. (2011). Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med. 9, 196.10.1186/1479-5876-9-115 - DOI - PMC - PubMed
    1. Attia P., Phan G. Q., Maker A. V., Robinson M. R., Quezado M. M., Yang J. C., Sherry R. M., Topalian S. L., Kammula U. S., Royal R. E., Restifo N. P., Haworth L. R., Levy C., Mavroukakis S. A., Nichol G., Yellin M. J., Rosenberg S. A. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–605310.1200/JCO.2005.06.205 - DOI - PMC - PubMed
    1. Aucouturier J., Ascarateil S., Dupuis L. (2006). The use of oil adjuvants in therapeutic vaccines. Vaccine 24(Suppl. 2), S2-44–S2-4510.1016/j.vaccine.2005.12.006 - DOI - PubMed
    1. Bachmann M. F., Kohler G., Ecabert B., Mak T. W., Kopf M. (1999). Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163, 1128–1131 - PubMed

LinkOut - more resources